ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptimmune Therapeutics PLC
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026
- Market cap
- $55.46M
- P/E (TTM)
- –
- Dividend yield
- –
Adaptimmune Therapeutics statistics
Financials through Jun 30, 2025, price-based ratios appear once a share price is available, median of Biological Products, (No Diagnostic Substances) companies for comparison
Income (trailing twelve months)
| Measure | Adaptimmune Therapeutics | Industry median |
|---|---|---|
| Revenue | $65.09M | $57.94M |
| Operating Income | -$164.22M | -$21.49M |
| Pretax Income | -$166.05M | -$14.72M |
| Net Income | -$169.76M | -$22.46M |
| EBITDA | -$164.22M | -$17.14M |
| EPS (Diluted) | -$0.11 | -$0.83 |
Margins
| Measure | Adaptimmune Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -252.3% | -44.5% |
| Pretax Margin | -255.1% | -13.0% |
| Profit Margin | -260.8% | -39.2% |
| EBITDA Margin | -252.3% | -31.3% |
| FCF Margin | -294.5% | -8.85% |
Returns
| Measure | Adaptimmune Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -129.9% | -41.0% |
| Return on Capital Employed (ROCE) | -207.6% | -38.0% |
Growth
| Measure | Adaptimmune Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | 207.1% | 2.25% |
| Revenue Growth (5Y CAGR) | 175.5% | 6.42% |
Balance sheet
| Measure | Adaptimmune Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $26.06M | $62.64M |
| Total Debt | $25.68M | $120.13M |
| Net Cash (Debt) | $386.00K | $15.77M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | -$70.96M | $48.61M |
| Book Value Per Share | -$0.04 | $1.36 |
| Tangible Book Value | -$74.77M | $23.01M |
| Working Capital | $26.60M | $75.09M |
Financial position
| Measure | Adaptimmune Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.52 | 3.30 |
| Quick Ratio | 0.69 | 2.39 |
| Interest Coverage | -28.99 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Adaptimmune Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$190.03M | -$12.39M |
| Capital Expenditures | -$1.64M | -$1.07M |
| Free Cash Flow | -$191.67M | -$20.34M |
| FCF Per Share | -$0.12 | -$0.42 |
Efficiency
| Measure | Adaptimmune Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.50 | 0.38 |
| Revenue Per Employee | $128.63K | $398.96K |
| Profits Per Employee | -$335.49K | -$705.27K |
| Employee Count | 506 | 74 |
Shares
| Measure | Adaptimmune Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 1,590,310,000 | 58,139,000 |
| Shares Change (QoQ) | 2.79% | 0.54% |
| Float | 1,589,250,000 | 49,154,900 |
| Shares Held by Insiders | 0.07% | 11.6% |
| Shares Held by Institutions | 0.00% | 59.4% |
Taxes
| Measure | Adaptimmune Therapeutics | Industry median |
|---|---|---|
| Income Tax | $3.71M | $89.00K |
Scores
| Measure | Adaptimmune Therapeutics | Industry median |
|---|---|---|
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Adaptimmune Therapeutics's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.